The Filing Desk

Cerenome

CNSY · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CNSY · Last close · November 19, 2026
$0.70
Value Cerenome yourself

Cerenome's revenue fell 10.5% to $5 million in fiscal 2025. Its operating margin was −293.5%, down from −252.3% a year earlier. Free cash flow was −$21 million. The diluted share count rose 910.4%.

CERENOME, INC. Latest fiscal year ended December 31, 2025 10-K filed March 12, 2026 · 0001193125-26-104258 Updated
Revenue
$5M
10.5%
Operating margin
−293.5%
41.1 pts
Net income
−$22M
 
Free cash flow
−$21M
 
Return on equity
—
 
Market cap
$5M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for stock splits (1-for-14.9254 and 1-for-50 and 1-for-10), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Cerenome does

Cerenome, which filed this annual report under its former name, Plus Therapeutics, is a Houston, Texas, healthcare company working on tests and radiation drugs for cancers of the brain and spinal cord. Its subsidiary CNSide Diagnostics sells the CNSide test, a laboratory test of spinal fluid that looks for tumor cells that have spread to the central nervous system in patients with carcinomas and melanomas. It relaunched the test in August 2025, and national agreements with UnitedHealthcare and Humana give it access to more than 67 million covered lives.

Its main drug candidate, rhenium (186Re) obisbemeda, puts a radioactive substance inside tiny fat particles and delivers it through a catheter straight into a brain tumor, to give a high dose of radiation in a single treatment while sparing healthy tissue. It is in clinical trials for recurrent glioblastoma, cancer that has spread to the lining of the brain and spine, and children's brain cancers. A second candidate is meant to treat liver cancers through an injection into an artery.

The company has no approved drugs. Its revenue so far is mainly grant money: it recognized $5.2 million in 2025 from a Texas cancer research grant of up to $17.6 million, and it also has US government awards for its trials.

Its biggest risks, as it describes them

  • Continued losses and a need for substantial new funding, which raise substantial doubt about its ability to continue as a going concern.
  • Losing its Nasdaq listing if it cannot meet the exchange's minimum stockholders' equity requirement.
  • Clinical trials may fail, take longer than planned, or not lead to approval of its drug candidates.
  • Its reliance on government grants and awards, which come with conditions and depend on continued funding.
  • Doctors and insurers may not accept or pay for its test and treatments.
From Cerenome's annual report on Form 10-K, filed March 12, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Cerenome lost money in fiscal 2025: a net loss of $22 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments18189413
Debt incl. finance leases75———
Net debt (negative means net cash)−12−13———
Net debt to EBITDA—————
Debt to equity0.6x0.8x———
Interest coverage−13.4x−27.7x−33.7x−82.1x−27.9x
Current ratio3.4x1.8x0.9x0.3x1.2x
Quick ratio3.4x1.8x0.9x0.3x1.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Cerenome's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Cerenome reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40—−165.2%−410.3%
Altman Z''−146.04−268.21−107.82
Accruals ratio−2.6%−26.9%−14.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets—PassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Cerenome side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CerenomeFY25−10.5%−293.5%−399.8%———
DBV TechnologiesFY2535.8%−2,609.2%−2,159.6%———Compare
Abeona TherapeuticsFY25—−1,536.9%−1,448.5%———Compare
Prime MedicineFY2555.3%−4,498.1%−3,607.4%———Compare
OcugenFY258.8%−1,425.7%−1,295.0%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue534————565
Revenue growth−3.8%−42.2%36.5%—————18.5%−10.5%
Gross profit202———————
Research and development161265351010118
Operating income−20−21−9−4−10−12−20−13−15−15
Net income−22−23−13−11−8−13−20−13−13−22
Diluted EPS (US$)−9,600.00−6,172.50−1,304.70−124.05−27.90−16.65−11.58−4.24−2.34−0.29
Diluted shares (millions)00000123878
Cash flow
Cash from operations−20−18−12−6−8−10−13−13−11−21
Capital expenditure0000———000
Free cash flow−20−18−12−6———−13−11−21
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation1100011102
Balance sheet at fiscal year end
Cash and short-term investments—10518818189413
Debt incl. finance leases18141411675———
Total assets3532242312222411716
Total liabilities2419192291117131612
Shareholders' equity1113513116−1−94
Margins and ratios
Gross margin41.7%5.4%68.7%———————
Operating margin−423.2%−769.2%−238.7%————−271.1%−252.3%−293.5%
Net margin−473.5%−843.7%−344.2%————−271.0%−222.8%−429.4%
Free cash flow margin−421.0%−685.1%−329.8%————−264.8%−183.7%−399.8%
Rule of 40 (growth + FCF margin)−424.7%−727.4%−293.3%—————−165.2%−410.3%
Return on capital——−44.3%−65.4%——————
Return on equity−190.1%−189.2%−138.6%−341.0%−393.3%−193.2%−234.7%−522.5%——
Return on assets−61.0%−68.5%−45.4%−46.1%−46.6%−78.6%−88.4%−75.5%−144.0%−195.0%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Cerenome's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Cerenome.